Bioanalysis, Drug Metabolism and New Drug Discovery

$3,458,473ZIAFY2023AGNIH

National Institute On Aging

Investigators

Linked publications & trials

Paper 37350292 Paper 36565852 Paper 36515353 Paper 35501309 Paper 32585682 Paper 32376872 Paper 32333098 Paper 32252062 Paper 32196924 Paper 31732715 Paper 30874790 Paper 30116859 Paper 29788121 Paper 29070563 Paper 28981653 Paper 28640272 Paper 28329397 Paper 28122695 Paper 27914737 Paper 27503249 Paper 27469513 Paper 27367973 Paper 27322559 Paper 27294788 Paper 27281303 Paper 27211567 Paper 27144355 Paper 27096720 Paper 27029859 Paper 27017097 Paper 26171236 Paper 26140427 Paper 25440059 Paper 25331415 Paper 25056852 Paper 24936922 Paper 24247087 Paper 23872161 Paper 23274708 Paper 23183107 Paper 22776956 Paper 22744891 Paper 22612619 Paper 22516044 Paper 22434858 Paper 22401348 Paper 22298121 Paper 22295895 Paper 22037294 Paper 21618615 Paper 21360034 Paper 21071556 Paper 20875593 Paper 20803495 Paper 20648207 Paper 20228869 Paper 20144591 Paper 20039779 Paper 20036561 Paper 19625153 Paper 19559878 Paper 19162477 Paper 18838481 Paper 18778830 Paper 18617349 Paper 18602637 Paper 18554995 Paper 17951120 Paper 17037905 Paper 16382125 Paper 16297925 Paper 16023900 Paper 15909525 Paper 15661431 Paper 15641484 Paper 15336363 Paper 15258102 Paper 15257070 Paper 15081923 Paper 11865668 Paper 11401311 Paper 10952478 Paper 10792207

Abstract

In patients suffering from treatment-resistant bipolar depression (BP) and with unresponsive chronic pain that is diagnosed as Complex Regional Pain Syndrome (CRPS)have responded to treatment with ketamine. The CRPS patients were treated with a five-day infusion of the drug produced pain relief in 75% of the patients and 67% of the BP responded after a single dose. Our studies indicates that the therapeutic activity of ketamine is due, in part, to (2R,6R)-hydroxynorketamine and dehydronorketamine and the pharmacological activities of the compounds have been investigated. In addition, metabolomic studies have determined that response and non-response to treatment with ketamine in BP patients is related to mitochodrial function and proteomic studies have also been recently carried out. This relationship is under investigation.

View original record on NIH RePORTER →